Advancements in computational models and statistical methods continue to refine the BMD approach. Recent developments include the integration of biological data to better understand mechanisms of action and improve dose-response modeling. Moreover, efforts are being made to harmonize BMD methodologies across regulatory agencies globally, enhancing the consistency and comparability of risk assessments. Researchers are also exploring the use of in vitro and in silico methods to supplement traditional animal testing, which could lead to more ethical and cost-effective approaches for determining BMDs.
